Overview
Oncology healthcare professionals who treat patients with lung cancer have an increasing array of diagnostic and therapeutic tools at their disposal. These include the use of immunotherapy and targeted therapy in early-stage and locally advanced disease, as well as in metastatic lung cancer. Additionally, new classes of agents have become available, such as bispecific antibodies and antibody-drug conjugates. These developments have the potential to improve outcomes for patients with lung cancer, but also bring new considerations for implementation, including adequate testing and adverse event management.
The 27th Annual International Lung Cancer Congress® will distill the latest data on targeted agents, immunotherapy, surgery, and radiation oncology for the management of lung cancer. This event also will include a special visionary session with the annual Addario Keynote Lecture and an expert panel discussion on coming trends in lung cancer therapy over the next decade. As in previous years, cutting-edge lectures, multidisciplinary case-based tumor boards, and question-and-answer sessions will allow participants to engage with international and national experts as they share their perspectives and personal experiences of clinical challenges and ongoing controversies in lung cancer management.
Learning Objectives
Upon completion of this activity, learners will be better able to:
- Describe the role of biomarkers and testing strategies to optimize and personalize treatment selection in patients with lung cancer
- Analyze recent clinical trial evidence as well as ongoing trials for the management of patients with lung cancer
- Formulate approaches to integrate monotherapy and combination immunotherapeutic approaches in the management of patients with lung cancer
- Develop strategies to integrate targeted and cytotoxic agents for the management of patients with lung cancer
- Discuss approaches to address disparities in care for patients with lung cancer
Program Co-Chairs
Roy S. Herbst, MD, PhD; Sandip Patel, MD; Heather Wakelee, MD, FASCO
To view full profile, click on the Program Co-Chairs tab above.
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Professor of Pharmacology
Deputy Director, Yale Cancer Center
Chief of Medical Oncology and Hematology
Yale Cancer Center and Smilow Cancer Hospital
Yale School of Medicine
New Haven, CT
Sandip Patel, MD
Professor of Medicine
Leader, Experimental Therapeutics
Coleader, Solid Tumor Therapeutics Program
Deputy Director, Sanford Stem Cell Clinical Center
Medical Director, Clinical Research Informatics
UC San Diego Health
San Diego, CA
Heather Wakelee, MD, FASCO
Professor of Medicine
Deputy Director
Stanford Cancer Institute
Chief, Division of Oncology
Stanford University School of Medicine
Stanford, CA
Click the button below to view all faculty presenters.
Physicians
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medical Oncologists (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Nurses
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 13.0 Contact Hours (Day 1 = 8.0; Day 2 = 5.0).
(Please note: The CE credit/MOC point amounts above include credit/points for the main session presentations and the Spotlight CE Sessions.)
This activity is supported by an educational grant from AbbVie, Inc.; AstraZeneca Pharmaceuticals, Exact Sciences Corporation, Merck & Co, Inc., and Partner Therapeutics, Inc.
Additional support for the Spotlight CE Session is provided by an educational grant from AbbVie, Inc.
PER is proud to partner with Lungevity, GO2 for Lung Cancer, Addario Lung Cancer Medical Institute (ALCMI), and International Association For the Study of Lung Cancer(IASLC).
